Oncogenic dependency on STAT3 serine phosphorylation in KRAS mutant lung cancer.
Journal
Oncogene
ISSN: 1476-5594
Titre abrégé: Oncogene
Pays: England
ID NLM: 8711562
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
received:
30
10
2020
accepted:
23
11
2021
revised:
15
11
2021
pubmed:
4
12
2021
medline:
24
2
2022
entrez:
3
12
2021
Statut:
ppublish
Résumé
The oncogenic potential of the latent transcription factor signal transducer and activator of transcription (STAT)3 in many human cancers, including lung cancer, has been largely attributed to its nuclear activity as a tyrosine-phosphorylated (pY
Identifiants
pubmed: 34857889
doi: 10.1038/s41388-021-02134-4
pii: 10.1038/s41388-021-02134-4
doi:
Substances chimiques
Serine
452VLY9402
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
809-823Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Wong MCS, Lao XQ, Ho KF, Goggins WB, Tse SLA. Incidence and mortality of lung cancer: global trends and association with socioeconomic status. Sci Rep. 2017;7:14300–9.
pubmed: 29085026
pmcid: 5662733
doi: 10.1038/s41598-017-14513-7
Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ Jr, Wu YL, et al. Lung cancer: current therapies and new targeted treatments. Lancet. 2017;389:299–311.
pubmed: 27574741
doi: 10.1016/S0140-6736(16)30958-8
Wang X, Goldstein D, Crowe PJ, Yang JL. Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence. Onco Targets Ther. 2016;9:5461–73.
pubmed: 27660463
pmcid: 5021053
doi: 10.2147/OTT.S94745
Noonan KL, Ho C, Laskin J, Murray N. The influence of the evolution of first-line chemotherapy on steadily improving survival in advanced non-small-cell lung cancer clinical trials. J Thorac Oncol. 2015;10:1523–31.
pubmed: 26536194
doi: 10.1097/JTO.0000000000000667
Walser T, Cui X, Yanagawa J, Lee JM, Heinrich E, Lee G, et al. Smoking and lung cancer: the role of inflammation. Proc Am Thorac Soc. 2008;5:811–5.
pubmed: 19017734
pmcid: 4080902
doi: 10.1513/pats.200809-100TH
Ahrendt S, Decker PA, Alawi EA, Zhu YR, Sanchez-Cespedes M, Yang SC, et al. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer. 2001;92:1525–30.
pubmed: 11745231
doi: 10.1002/1097-0142(20010915)92:6<1525::AID-CNCR1478>3.0.CO;2-H
Westra WH, Slebos RJ, Offerhaus GJ, Goodman SN, Evers SG, Kensler TW, et al. K-ras oncogene activation in lung adenocarcinomas from former smokers: evidence that K-ras mutations are an early and irreversible event in the development of adenocarcinoma of the lung. Cancer. 1993;72:432–8.
pubmed: 8319174
doi: 10.1002/1097-0142(19930715)72:2<432::AID-CNCR2820720219>3.0.CO;2-#
Román M, Baraibar I, López I, Nadal E, Rolfo C, Vicent S, et al. KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target. Mol Cancer. 2018;17:33.
pubmed: 29455666
pmcid: 5817724
doi: 10.1186/s12943-018-0789-x
Jackson E, Willis N, Mercer K, Bronson RT, Crowley D, Montoya R, et al. DA. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 2001;15:3243–8.
pubmed: 11751630
pmcid: 312845
doi: 10.1101/gad.943001
DuPage M, Dooley AL, Jacks T. Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat Protoc. 2009;4:1064–72.
pubmed: 19561589
pmcid: 2757265
doi: 10.1038/nprot.2009.95
Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ. Drugging the undruggable RAS: Mission possible? Nat Rev Drug Discov. 2014;13:828–51.
pubmed: 25323927
pmcid: 4355017
doi: 10.1038/nrd4389
Janes MR, Zhang J, Li LS, Hansen R, Peters U, Guo X, et al. Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor. Cell. 2018;172:578–89.
pubmed: 29373830
doi: 10.1016/j.cell.2018.01.006
Zhu Z, Aref A, Cohoon TJ, Barbie TU, Imamura Y, Yang S, et al. Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit. Cancer Discov. 2014;4:452–65.
pubmed: 24444711
pmcid: 3980023
doi: 10.1158/2159-8290.CD-13-0646
Brooks GD, McLeod L, Alhayyani S, Miller A, Russell PA, Ferlin W, et al. IL6 Trans-signaling promotes KRAS-driven lung carcinogenesis. Cancer Res. 2016;76:866–76.
pubmed: 26744530
doi: 10.1158/0008-5472.CAN-15-2388
Saad MI, Alhayyani S, McLeod L, Yu L, Alanazi M, Deswaerte V, et al. ADAM17 selectively activates the IL-6 trans-signaling/ERK MAPK axis in KRAS-addicted lung cancer. EMBO Mol Med. 2019;11:e9976.
pubmed: 30833304
pmcid: 6460353
doi: 10.15252/emmm.201809976
Kim HS, Park YH, Lee J, Ahn JS, Kim J, Shim YM, et al. Clinical impact of phosphorylated signal transducer and activator of transcription 3, epidermal growth factor receptor, p53, and vascular endothelial growth factor receptor 1 expression in resected adenocarcinoma of lung by using tissue microarray. Cancer. 2010;116:676–85.
pubmed: 20052735
doi: 10.1002/cncr.24748
Tong M, Wang J, Jiang N, Pan H, Li D. Correlation between p-STAT3 overexpression and prognosis in lung cancer: a systematic review and meta-analysis. PLoS One. 2017;12:e0182282.
pubmed: 28797050
pmcid: 5552221
doi: 10.1371/journal.pone.0182282
Yang Q, Shen S, Zhou S, Ni J, Chen D, Wang G, et al. STAT3 activation and aberrant ligand-dependent sonic hedgehog signaling in human pulmonary adenocarcinoma. Exp Mol Pathol. 2012;93:227–36.
pubmed: 22554932
doi: 10.1016/j.yexmp.2012.04.009
Tran P, Fan AC, Bendapudi PK, Koh S, Komatsubara K, Chen J, et al. Combined Inactivation of MYC and K-Ras oncogenes reverses tumorigenesis in lung adenocarcinomas and lymphomas. PLoS One. 2008;3:e2125.
pubmed: 18461184
pmcid: 2365560
doi: 10.1371/journal.pone.0002125
Li Y, Du H, Qin Y, Roberts J, Cummings OW, Yan C. Activation of the signal transducers and activators of the transcription 3 pathway in alveolar epithelial cells induces inflammation and adenocarcinomas in mouse lung. Cancer Res. 2007;67:8494–503.
pubmed: 17875688
doi: 10.1158/0008-5472.CAN-07-0647
Yu H, Lee H, Herrmann A, Buettner R, Jove R. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer. 2014;14:736–46.
pubmed: 25342631
doi: 10.1038/nrc3818
Poli V, Camporeale A. STAT3-mediated metabolic reprograming in cellular transformation and implications for drug resistance. Front Oncol. 2015;5:121.
pubmed: 26106584
pmcid: 4459099
doi: 10.3389/fonc.2015.00121
Jones SA, Jenkins BJ. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat Rev Immunol. 2018;18:773–89.
pubmed: 30254251
doi: 10.1038/s41577-018-0066-7
Gough D, Corlett A, Schlessinger K, Wegrzyn J, Larner AC, Levy DE. Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. Science. 2009;324:1713–6.
pubmed: 19556508
pmcid: 2840701
doi: 10.1126/science.1171721
Wegrzyn J, Potla R, Chwae YJ, Sepuri NB, Zhang Q, Koeck T, et al. Function of mitochondrial Stat3 in cellular respiration. Science. 2009;323:793–7.
pubmed: 19131594
pmcid: 2758306
doi: 10.1126/science.1164551
Gough DJ, Marie I, Lobry C, Aifantis I, Levy DE. STAT3 supports experimental K-RasG12D–induced murine myeloproliferative neoplasms dependent on serine phosphorylation. Blood. 2014;124:2252–61.
pubmed: 25150294
pmcid: 4183984
doi: 10.1182/blood-2013-02-484196
Garama DJ, White CL, Balic JJ, Gough DJ. Mitochondrial STAT3: powering up a potent factor. Cytokine. 2016;87:20–25.
pubmed: 27269970
doi: 10.1016/j.cyto.2016.05.019
Balic JJ, Garama DJ, Saad M, Yu L, West A, West AJ, et al. Serine-phosphorylated STAT3 promotes tumorigenesis via modulation of RNA polymerase transcriptional activity. Cancer Res. 2019;79:5272–87.
pubmed: 31481496
doi: 10.1158/0008-5472.CAN-19-0974
Shen Y, Schlessinger K, Zhu X, Meffre E, Quimby F, Levy DE, et al. Essential role of STAT3 in postnatal survival and growth revealed by mice lacking STAT3 serine 727 phosphorylation. Mol Cell Biol. 2004;24:407–19.
pubmed: 14673173
pmcid: 303338
doi: 10.1128/MCB.24.1.407-419.2004
Wen Z, Zhong Z, Darnell JE Jr. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell. 1995;82:241–50.
pubmed: 7543024
doi: 10.1016/0092-8674(95)90311-9
Zouein FA, Zgheib C, Hamza S, Fuseler JW, Hall JE, Soljancic A, et al. Role of STAT3 in angiotensin II-induced hypertension and cardiac remodeling revealed by mice lacking STAT3 serine 727 phosphorylation. Hypertens Res. 2013;36:496–503.
pubmed: 23364341
pmcid: 3674130
doi: 10.1038/hr.2012.223
Johnson L, Mercer K, Greenbaum D, Bronson RT, Crowley D, Tuveson DA, et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature. 2001;410:1111–6.
pubmed: 11323676
doi: 10.1038/35074129
Jerome-Marson V, Mazieres J, Groussard O, Garcia O, Berjaud J, Dahan M, et al. Expression of TTF-1 and cytokeratins in primary and secondary epithelial lung tumours: correlation with histological type and grade. Histopathology. 2004;45:125–34.
pubmed: 15279630
doi: 10.1111/j.1365-2559.2004.01893.x
Kortlever RM, Sodir N, Wilson CH, Burkhart DL, Pellegrinet L, Brown Swigart L, et al. Myc cooperates with Ras by programming inflammation and immune suppression. Cell. 2017;171:1301–15.
pubmed: 29195074
pmcid: 5720393
doi: 10.1016/j.cell.2017.11.013
Dragoj M, Milosevic Z, Bankovic J, Dinic J, Pesic M, Tanic N, et al. Association of CCND1 overexpression with KRAS and PTEN alterations in specific subtypes of non-small cell lung carcinoma and its influence on patients’ outcome. Tumour Biol. 2015;36:8773–80.
pubmed: 26055143
doi: 10.1007/s13277-015-3620-y
Soucek L, Whitfield J, Martins CP, Finch AJ, Murphy DJ, Sodir NM, et al. Modelling Myc inhibition as a cancer therapy. Nature. 2008;455:679–83.
pubmed: 18716624
pmcid: 4485609
doi: 10.1038/nature07260
Murphy DJ, Junttila MR, Pouyet L, Karnezis A, Shchors K, Bui DA, et al. Distinct thresholds govern Myc’s biological output in vivo. Cancer Cell. 2008;14:447–57.
pubmed: 19061836
doi: 10.1016/j.ccr.2008.10.018
Dutta P, Zhang L, Zhang H, Peng Q, Montgrain PR, Wang Y, et al. Unphosphorylated STAT3 in heterochromatin formation and tumor suppression in lung cancer. BMC Cancer. 2020;20:145.
pubmed: 32087696
pmcid: 7036253
doi: 10.1186/s12885-020-6649-2
Ji H, Houghton A, Mariani TJ, Perera S, Kim CB, Padera R, et al. K-ras activation generates an inflammatory response in lung tumors. Oncogene. 2006;25:2105–12.
pubmed: 16288213
doi: 10.1038/sj.onc.1209237
McClelland MR, Carskadon SL, Zhao L, White ES, Beer DG, Orringer MB, et al. Diversity of the angiogenic phenotype in non–small cell lung cancer. Am J Respir Cell Mol Biol. 2007;36:343–50.
pubmed: 17079777
doi: 10.1165/rcmb.2006-0311OC
Liou GY, Doppler H, DelGiorno KE, Zhang L, Leitges M, Crawford HC, et al. Mutant KRas-induced mitochondrial oxidative stress in acinar cells upregulates EGFR signaling to drive formation of pancreatic precancerous lesions. Cell Rep. 2016;14:2325–36.
pubmed: 26947075
pmcid: 4794374
doi: 10.1016/j.celrep.2016.02.029
Weinberg F, Hamanaka R, Wheaton WW, Weinberg S, Joseph J, Lopez M, et al. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci USA. 2010;107:8788–93.
pubmed: 20421486
pmcid: 2889315
doi: 10.1073/pnas.1003428107
Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029–33.
doi: 10.1126/science.1160809
Stine ZE, Walton Z, Altman BJ, Hsieh AL, Dang CV. MYC, metabolism, and cancer. Cancer Discov. 2015;5:1024–39.
pubmed: 26382145
pmcid: 4592441
doi: 10.1158/2159-8290.CD-15-0507
Bowman T, Broome MA, Sinibaldi D, Wharton W, Pledger WJ, Sedivy JM, et al. Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc Natl Acad Sci USA. 2001;98:7319–24.
pubmed: 11404481
pmcid: 34666
doi: 10.1073/pnas.131568898
Yu L, Wu D, Gao H, Balic J, Tsykin A, Han T-S, et al. Clinical utility of a STAT3-regulated microRNA-200 family signature with prognostic potential in early gastric cancer. Clin Cancer Res. 2018;24:1459–72.
pubmed: 29330205
doi: 10.1158/1078-0432.CCR-17-2485
Niu G, Briggs J, Deng J, Ma Y, Lee H, Kortylewski M, et al. Signal transducer and activator of transcription 3 is required for hypoxia-inducible factor-1alpha RNA expression in both tumor cells and tumor-associated myeloid cells. Mol Cancer Res. 2008;6:1099–105.
pubmed: 18644974
pmcid: 2775817
doi: 10.1158/1541-7786.MCR-07-2177
Nagao A, Kobayashi M, Koyasu S, Chow CCT, Harada H. HIF-1-dependent reprogramming of glucose metabolic pathway of cancer cells and its therapeutic significance. Int J Mol Sci. 2019;20:E238.
pubmed: 30634433
doi: 10.3390/ijms20020238
Hirahara K, Onodera A, Villarino AV, Bonelli M, Sciumè G, Laurence A, et al. Asymmetric action of STAT transcription factors drives transcriptional outputs and cytokine specificity. Immunity. 2015;42:877–89.
pubmed: 25992861
doi: 10.1016/j.immuni.2015.04.014
Costa-Pereira AP, Tininini S, Strobl B, Alonzi T, Schlaak JF, Is’harc H, et al. Mutational switch of an IL-6 response to an interferon-gamma-like response. Proc Natl Acad Sci USA. 2002;99:8043–7.
pubmed: 12060750
pmcid: 123017
doi: 10.1073/pnas.122236099
Yu C, Huo X, Agoston AT, Zhang X, Theiss AL, Cheng E, et al. Mitochondrial STAT3 contributes to transformation of Barrett’s epithelial cells that express oncogenic Ras in a p53-independent fashion. Am J Physiol Gastrointest Liver Physiol. 2015;309:G146–161.
pubmed: 26045618
pmcid: 4525109
doi: 10.1152/ajpgi.00462.2014
Song L, Turkson J, Karras JG, Jove R, Haura EB. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene. 2003;22:4150–65.
pubmed: 12833138
doi: 10.1038/sj.onc.1206479
Zhou J, Qu Z, Yan S, Sun F, Whitsett JA, Shapiro SD, et al. Differential roles of STAT3 in the initiation and growth of lung cancer. Oncogene. 2015;34:3804–14.
pubmed: 25284582
doi: 10.1038/onc.2014.318
Grabner B, Schramek D, Mueller KM, Moll HP, Svinka J, Hoffmann T, et al. Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis. Nat Commun. 2015;6:6285–98.
pubmed: 25734337
doi: 10.1038/ncomms7285
Caetano MS, Hassane M, Van HT, Bugarin E, Cumpian AM, McDowell CL, et al. Sex specific function of epithelial STAT3 signaling in pathogenesis of K-ras mutant lung cancer. Nat Commun. 2018;9:4589.
pubmed: 30389925
pmcid: 6214980
doi: 10.1038/s41467-018-07042-y
Meissl K, Macho-Maschler S, Müller M, Strobl B. The good and the bad faces of STAT1 in solid tumours. Cytokine. 2017;89:12–20.
pubmed: 26631912
doi: 10.1016/j.cyto.2015.11.011
Takeda K, Clausen BE, Kaisho T, Tsujimura T, Terada N, Förster I, et al. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity. 1999;10:39–49.
pubmed: 10023769
doi: 10.1016/S1074-7613(00)80005-9
Sano S, Itami S, Takeda K, Tarutani M, Yamaguchi Y, Miura H, et al. Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis. EMBO J. 1999;4657–68.
Zhu S, Phatarpekar P, Denman CJ, Senyukov VV, Somanchi SS, Nguyen-Jackson HT, et al. Transcription of the activating receptor NKG2D in natural killer cells is regulated by STAT3 tyrosine phosphorylation. Blood. 2014;124:403–11.
pubmed: 24891320
pmcid: 4102712
doi: 10.1182/blood-2013-05-499707
D’Amico S, Shi J, Martin BL, Crawford HC, Petrenko O, Reich NC. STAT3 is a master regulator of epithelial identity and KRAS-driven tumorigenesis. Genes Dev. 2018;32:1175–87.
pubmed: 30135074
pmcid: 6120712
doi: 10.1101/gad.311852.118
Oft M. IL-10: master switch from tumor-promoting inflammation to antitumor immunity. Cancer Immunol Res. 2014;2:194–9.
pubmed: 24778315
doi: 10.1158/2326-6066.CIR-13-0214
Li F, Wang Y, Zeller KI, Potter JJ, Wonsey DR, O’Donnell KA, et al. Myc stimulates nuclearly encoded mitochondrial genes and mitochondrial biogenesis. Mol Cell Biol. 2005;25:6225–34.
pubmed: 15988031
pmcid: 1168798
doi: 10.1128/MCB.25.14.6225-6234.2005
Han YH, Sim HK, Kim SZ, Park WH. Antimycin A as a mitochondrial electron transport inhibitor prevents the growth of human lung cancer A549 cells. Oncol Rep. 2008;20:689–93.
pubmed: 18695925
Bretones G, Delgado M, León J. Myc and cell cycle control. Biochim Biophys Acta. 2015;1849:506–16.
pubmed: 24704206
doi: 10.1016/j.bbagrm.2014.03.013
Macias E, Rao D, Carbajal S, Kiguchi K, DiGiovanni J. Stat3 binds to mtDNA and regulates mitochondrial gene expression in keratinocytes. J Invest Dermatol. 2014;134:1971–80.
pubmed: 24496235
pmcid: 4057971
doi: 10.1038/jid.2014.68
Mao YQ, Houry WA. The role of pontin and reptin in cellular physiology and cancer etiology. Front Mol Biosci. 2017;4:58.
pubmed: 28884116
pmcid: 5573869
doi: 10.3389/fmolb.2017.00058
Weng MT, Luo J. The enigmatic ERH protein: its role in cell cycle, RNA splicing and cancer. Protein Cell. 2013;4:807–12.
pubmed: 24078386
pmcid: 4875447
doi: 10.1007/s13238-013-3056-3
Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol. 2010;8:e1000412.
pubmed: 20613859
pmcid: 2893951
doi: 10.1371/journal.pbio.1000412
Garassino MC, Marabese M, Rusconi P, Rulli E, Martelli O, Farina G, et al. Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer. Ann Oncol. 2011;22:235–7.
pubmed: 21169473
doi: 10.1093/annonc/mdq680
Ruwanpura SM, McLeod L, Miller A, Jones J, Bozinovski S, Vlahos R, et al. Interleukin-6 promotes pulmonary emphysema associated with apoptosis in mice. Am J Respir Cell Mol Biol. 2011;45:720–30.
pubmed: 21297079
doi: 10.1165/rcmb.2010-0462OC
Liu YD, Yu L, Ying L, Balic J, Gao H, Deng NT, et al. Toll-like receptor 2 regulates metabolic reprogramming in gastric cancer via superoxide dismutase 2. Int J Cancer. 2019;144:3056–69.
pubmed: 30536754
pmcid: 6590666
doi: 10.1002/ijc.32060